101355Smart Combination Respiratory Medicines for Optimal & Cost Effective Patient BenefitClosedCollaborative R&DInnovate UKThe Business-led APPS2B Project aims to identify, demonstrate, and quantify for the first time the mechanism for, and potential significant clinical benefits of hihghly innovative orally inhaled combination respiratory therapies, that have been optimally designed, engineered and manufactured for intent using Prosonix Multi-Component Particle (MCP) Technology.